FDAnews
www.fdanews.com/articles/134146-pervasis-hemodialysis-treatment-gets-fast-track-review

Pervasis Hemodialysis Treatment Gets Fast-Track Review

February 9, 2011
The U.S. Food and Drug Administration has granted fast track review status to Cambridge biotech Pervasis Therapeutics Inc. for Vascugel, its lead drug program, a prevention treatment of kidney dialysis access failure in patients with end stage renal disease.
Mass High Tech